Current research and future developments in retinoids: oral and topical agents

Area of Science:

• Molecular pharmacology
• Drug discovery
• Gene transcription regulation

Background:

• Retinoids are small molecules that modulate gene transcription via nuclear receptors.
• Non-selective retinoids cause both beneficial and adverse effects.
• Rational drug design aims for receptor selectivity to mitigate side effects.

Purpose of the Study:

• To highlight the importance of selective retinoid drug design.
• To introduce tazarotene as an example of rational retinoid drug discovery.
• To discuss the therapeutic potential of novel retinoid receptor modulators.

Main Methods:

• Engineering tazarotene's molecular structure for selective RAR binding.
• Evaluating tazarotene's preferential activation of RAR beta and RAR gamma.
• Assessing tazarotene's favorable pharmacokinetic properties.

Main Results:

• Tazarotene demonstrates selectivity for retinoic acid receptors (RARs) over retinoid X receptors (RXRs).
• It preferentially activates RAR beta and RAR gamma subtypes.
• The drug possesses clinically favorable pharmacokinetic characteristics.

Conclusions:

• Rational drug design is crucial for developing selective retinoids.
• Tazarotene represents a successful application of this approach.
• New retinoid antagonists and inverse agonists offer future therapeutic avenues in dermatology, oncology, and metabolic diseases.